Parkinson's Disease Market Size is Estimated to Reach USD 6,705  Million by 2030

The Global Parkinson's Disease Market is expected to grow at a CAGR of around 11.5% from 2022 to 2030 and expected to reach the market value of around USD 6,705 Million by 2030.

Parkinson's Disease Market Report Key Highlights
• Global Parkinson's disease market size was USD 2,540 million in 2021 and is expected to grow at CAGR of 11.5% from 2022 to 2030
• North America Parkinson's disease market is expected to lead with more than 35% market share
• According to the National Institute of Health (NIH) estimates, there will be over 1.2 million people suffering from Parkinson's in the US by 2030
• Asia-Pacific Parkinson's disease market is expected to grow with fastest CAGR during the forecast period from 2022 to 2030
• Among drug classes, carbidopa/levodopa occupied more than 30% of the total market share

Request For Free Sample Report @
https://www.acumenresearchandconsulting.com/request-sample/2435

Parkinson's disease is a chronic and progressive disease that impairs the capacity to conduct daily tasks. It is a movement illness distinguished by its most prevalent motor-related symptoms, which include tremors (a type of rhythmic shaking), muscle stiffness or rigidity, and slowness of movement (called bradykinesia). The growing elderly population is the primary reason driving the global Parkinson's disease market revenue. According to our Parkinson's disease industry analysis, the increasing drug approval for these disorders is fueling the market demand. In addition, a robust pipeline of new drug development is a significant Parkinson's disease market trend that is strengthening the industry's growth. Furthermore, government funding for research is expected to drive the Parkinson's disease market growth.

Parkinson's Disease Market Dynamics and Opportunities

A strong pipeline of drugs by the manufacturer will offer lucrative opportunities for the Parkinson's disease market to grow

New product launches in the global market for the treatment of Parkinson's disease will assist the market to grow to its fullest. In February 2018, Adamas Pharmaceuticals, Inc. announced subgroup analyses of Parkinson's disease patients taking amantadine immediate release (IR) who are still experiencing dyskinesia and enrolled into EASE LID 2, the long-term. The ongoing phase 3 open-label study of GOCOVRI (amantadine) extended-release capsule results shows that there are around 35% improvements in motor applications. The safety and tolerability profile of this patient was observed to be consistent without any adverse effects. Additionally, most of the major players have a robust drug pipeline for the treatment of Parkinson's disease.

Market Restraint

The availability of alternative medical treatments will have a serious impact on the global Parkinson's disease market. Alternative treatment options and substitute products will have intense tussle between the competitors manufacturing the same drug. This will have an obstacle for the manufacturer to grow and launch new products in the market for the same form of the disease.

Check the detailed table of contents of the report @
https://www.acumenresearchandconsulting.com/table-of-content/parkinsons-disease-market

Parkinson's Disease Market Segmentation

Parkinson's disease market is segmented based on drug class and distribution channel, patient care settings, and regions. By drug class, the market is segmented based on carbidopa/levodopa, dopamine receptor agonists, MAO inhibitors, COMT-inhibitors, anticholinergics, and other drugs. Based on distribution channels, the market is segmented as hospital pharmacies, retailer pharmacies, and online pharmacies. In inpatient care settings the market is bifurcated into hospitals and clinics.

According to Parkinson's disease market forecast, the carbidopa/levodopa drug class will record a significant market share in the overall market. By distribution channel, hospital pharmacies will grow to their fullest in the coming years. Frequent visits to the rising patient pool for a consultation with doctors or physicians will positively influence the hospital pharmacies segment to grow to its fullest. Furthermore, in inpatient care settings, hospitals will continue their dominance till the forecast period with clinics recording the second largest market share in the future. The hospital segment will record the largest market share under the patient care setting segment. Also, the clinics segment is gaining fast pace and is predicted to record the second largest share of the global market for Parkinson's disease.

Parkinson's Disease Market Regional Outlook

North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa are the regional categorizations of the Parkinson's disease market industry.

North America will dominate the regional market for Parkinson's disease. The factor that contributes to regional growth involves highly prevalent groups suffering from Parkinson's disease. Additionally, the high prevalence observed in the aging population fuel the growth of the North America Parkinson's disease market. Nearly 1 million are living with Parkinson's disease in the US. This number is far greater than the combined number of people diagnosed with multiple sclerosis and muscular dystrophy according to the statistics released by the Parkinson's Foundation. The combined direct and indirect costs of Parkinson's involving treatment, social payment, and lost income is predicted to be nearly US$ 52 Bn per year in the US alone. Moreover, the Parkinson's Prevalence Project estimates that 930,000 people in the US are living with Parkinson's disease (PD) by 2020. This number is projected to rise to 1.2 million by 2030.

Buy this premium research report -
https://www.acumenresearchandconsulting.com/buy-now/0/2435

Parkinson's disease Market Players

Some of the key Parkinson's disease treatment companies include Teva, Novartis AG, GSK, AbbVie, Merck, Boehringer Ingelheim, Impax Laboratories, Lundbeck, UCB, Valeant Pharmaceuticals, Acadia, and others.

Some of the key observations regarding the Parkinson's disease industry include:
• In August 2020, Biogen announced collaboration with Denali on the LRRK2 program for Parkinson's disease and certain TV platform-enabled programs for neurodegenerative disease.
• In June 2016, ACADIA Pharmaceuticals announced the approval of NUPLAZID (pimavanserin) by the FDA. This is the first drug used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
• In June 2016, Sun Pharmaceuticals Ltd. announced a distribution agreement with Mitsubishi Tanabe Pharma Corporation (Japan) to distribute 14 prescription-related products involving Parkinson's disease drug Parlodel in Japan.

201, Vaidehi-Saaket, Baner - Pashan Link Rd, Pashan, Pune, Maharashtra 411021

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

This release was published on openPR.